Simultaneous Integrated Boost Radiotherapy in Unresectable Stage IV (M0) Head and Neck Squamous Cell Cancer Patients: Daily Clinical Practice.
Head and neck cancer
Intensity-Modulated radiotherapy (IMRT)
Radiotherapy
Simultaneous integrated boost (SIB)
Systemic therapies
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
22
05
2019
revised:
07
03
2020
accepted:
02
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
ppublish
Résumé
To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice. Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies. We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated. 37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months. SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.
Sections du résumé
AIM
OBJECTIVE
To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice.
BACKGROUND
BACKGROUND
Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies.
MATERIAL AND METHODS
METHODS
We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated.
RESULTS
RESULTS
37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months.
CONCLUSION
CONCLUSIONS
SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.
Identifiants
pubmed: 32368191
doi: 10.1016/j.rpor.2020.04.006
pii: S1507-1367(20)30062-6
pmc: PMC7190747
doi:
Types de publication
Journal Article
Langues
eng
Pagination
399-404Informations de copyright
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Références
Radiat Oncol. 2014 Dec 29;9:264
pubmed: 25544268
Crit Rev Oncol Hematol. 2016 Apr;100:147-66
pubmed: 26947812
Curr Probl Cancer. 2004 Jan-Feb;28(1):7-40
pubmed: 14688789
Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):21-32
pubmed: 10477002
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Crit Rev Oncol Hematol. 2015 Aug;95(2):191-213
pubmed: 25818202
Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):831-43
pubmed: 2921175
J Clin Oncol. 2005 May 1;23(13):3008-15
pubmed: 15860857
J Radiat Res. 2016 Aug;57 Suppl 1:i69-i75
pubmed: 27538846
J Contemp Brachytherapy. 2015 Aug;7(4):319
pubmed: 26622235
Head Neck. 2019 May;41(5):1490-1498
pubmed: 30835900
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
BMC Cancer. 2006 Jan 31;6:28
pubmed: 16448551
BMC Cancer. 2013 Dec 27;13:610
pubmed: 24373220
Cancer Radiother. 2005 Feb;9(1):42-50
pubmed: 15804619
Radiother Oncol. 2003 Dec;69(3):267-75
pubmed: 14644486
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24
pubmed: 25670541
World Neurosurg. 2017 Jul;103:702-712
pubmed: 28454993
JAMA. 2018 Sep 4;320(9):867-868
pubmed: 30105359
Neurosurg Rev. 2016 Jul;39(3):495-504
pubmed: 27106896
Laryngoscope. 2013 Dec;123(12):E97-103
pubmed: 23775348
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):931-8
pubmed: 17011465
Anticancer Res. 2015 Sep;35(9):4949-53
pubmed: 26254393
Support Care Cancer. 2014 Jul;22(7):1889-96
pubmed: 24566870
Radiat Oncol. 2011 Nov 22;6:162
pubmed: 22108341
Radiother Oncol. 1997 Apr;43(1):47-51
pubmed: 9165136
Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Feb;132(1):25-9
pubmed: 24924114
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1360-75
pubmed: 26780912
Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30
pubmed: 10701741
Tumori. 2012 Jan-Feb;98(1):66-78
pubmed: 22495704
Cancer Treat Rev. 2012 Dec;38(8):1033-49
pubmed: 22542950
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
Acta Oncol. 2001;40(6):712-7
pubmed: 11765065
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544